NCT06425705View on ClinicalTrials.gov

Impact of Silymarin Adjunct Therapy on Proteinuria in Type 2 Diabetic Patients on RAS Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

July 10, 2023

Study Completion Date

July 10, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Silymarin

140 mg of silymarin administered orally three times daily, alongside their standard treatment with renin-angiotensin system inhibitors.

DRUG

Placebo

placebo capsule three times a day alongside their standard treatment with renin-angiotensin system inhibitors.

Trial Locations (1)

54000

Lahore General Hospital, Lahore, Lahore

All Listed Sponsors
lead

Lahore General Hospital

OTHER_GOV